RxUtility Launches Personalized AI Companion Mimi™ to Compare Every Drug Price as Affordability Crisis Grows

Why It Matters

By delivering instant, personalized price transparency, Mimi could lower prescription abandonment rates and improve medication adherence, easing cost pressures on patients and the broader healthcare system.

Key Takeaways

• Mimi provides real‑time price comparison for every prescription.
• Beta is free, accessible via web at getmimi.ai.
• Targets 98 million annual prescription abandonments due to cost.
• Integrates via API for providers, pharmacies, employers, payers.
• AI uses curated data, insurance, coupons, cash discounts.

Pulse Analysis

The United States is grappling with a prescription‑affordability crisis, as surveys show more than six in ten adults worry about drug costs and nearly 98 million prescriptions are left unfilled each year. Traditional price‑lookup tools often provide fragmented data, leaving patients to guess which pharmacy offers the best deal. This opacity fuels non‑adherence, higher downstream medical expenses, and widening health inequities. In this environment, a solution that aggregates pricing across the entire pharmacy landscape and presents it in an intuitive format meets a critical market need.

Mimi leverages generative AI to conduct a brief, conversational interview, capturing key variables such as drug name, strength, insurance coverage and geographic location. Behind the scenes, RxUtility’s proprietary database pulls real‑time pricing from every major U.S. pharmacy, integrates manufacturer copay‑coupon programs, and calculates cash‑price discounts. The platform’s API‑first architecture enables seamless white‑label integration, allowing health systems, payers and employers to embed the tool directly into existing digital‑health workflows. This B2B2C model not only accelerates deployment—often within hours—but also ensures that end‑users receive consistent, high‑quality data without navigating multiple websites.

If widely adopted, Mimi could shift the economics of prescription purchasing by reducing the information asymmetry that drives price shopping fatigue. Greater price visibility is expected to boost initiation and continuation of therapy, translating into better health outcomes and lower overall spending for insurers and employers. Moreover, the data insights generated by widespread usage may inform policy discussions around drug pricing transparency, potentially prompting broader regulatory reforms. As the healthcare industry continues to digitize, tools like Mimi exemplify how AI can turn complex cost data into actionable, patient‑centric guidance.